Evidence-based recommendations on epiduroscopic lumbar discectomy through the sacral hiatus for sciatica in adults
Evidence-based recommendations on electroporation (electrical pulses sent through a needle into a tumour) for treating prostate cancer in adults
Evidence-based recommendations on lateral interbody fusion in the lumbar spine for low back pain
Evidence-based recommendations on sacrocolpopexy with hysterectomy (removal of womb) using mesh to repair uterine prolapse (prolapsed womb)
Evidence-based recommendations on minimally invasive sacroiliac joint fusion surgery for chronic sacroiliac pain (lower back pain)
Evidence-based recommendations on low-level laser therapy for preventing or treating oral mucositis caused by radiotherapy or chemotherapy
Evidence-based recommendations on electrically stimulated intravesical chemotherapy for non-muscle-invasive bladder cancer in adults
Evidence-based recommendations on platelet-rich plasma injections for knee osteoarthritis in adults (deterioration of the articular cartilage and menisci)
Evidence-based recommendations on collagen paste for closing an anal fistula in adults
Evidence-based recommendations on low-energy contact X-ray brachytherapy (the Papillon technique) for locally advanced rectal cancer in adults
October 2017: The device used in this procedure (Essure) no longer has a CE mark. The CE mark is necessary for medical devices to be used in EU countries. Therefore NICE has decided to suspend its guidance. NICE would consider whether to issue new guidance on “Hysteroscopic sterilisation by insertion of intrafallopian implants” should evidence including an appropriately CE marked device become available.
October 2018: The device used in this procedure (CyPass) has been withdrawn by the manufacturer Alcon, because of concerns about its long-term safety. Further details can be found in the Voluntary Field Safety Notice issued by Alcon. Surgeons are advised not to implant this device, to return any unused devices to Alcon and to consider reviewing any patients who have already been implanted with CyPass. Therefore NICE has decided to withdraw its guidance. NICE would consider whether to issue new guidance on ab interno supraciliary microstent insertion with phacoemulsification for primary open-angle glaucoma should evidence using an appropriately CE marked device become available.